Compare Incyte Corporation (INCY) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Royal Caribbean Cruises Ltd — how do they compare? Incyte Corporation trades at $117.86 (market cap $23.11B), while Royal Caribbean Cruises Ltd trades at $285.76 (market cap $76.75B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 3.3× Incyte Corporation's market cap, and Royal Caribbean Cruises Ltd pays a 1.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RCL | |
|---|---|---|
Market Cap | $23.11B | $76.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $365.84 |
52-Week Low | $67.38 | $246.71 |
Enterprise Value | $19.13B | $98.03B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Royal Caribbean (RCL) trades at $285.59, down 0.48% on the day, with technical indicators showing a neutral to bullish bias as the stock tests support near $285. Fundamentally, the company demonstrates strong profitability with 24.36% net margins and 50.41% ROE, supported by robust revenue growth from $8.8B in 2022 to $17.93B in 2025. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $3.60 surpassing estimates of $3.24.
The investment outlook remains positive given analyst consensus price target of $328 (15% upside), strong cash flow generation, and continued recovery in cruise demand. Key risks include high debt levels ($18.47B long-term debt), sensitivity to economic cycles, and competitive pressures in the cruise industry. The upcoming Q2 2026 earnings report on July 28 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
